Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Operating Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed Operating Margin for 6 consecutive years, with 8981.45% as the latest value for Q3 2023.

  • Quarterly Operating Margin fell 596133.0% to 8981.45% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 37938.04% through Jun 2024, down 3789045.0% year-over-year, with the annual reading at 59.51% for FY2023, 25465.0% up from the prior year.
  • Operating Margin for Q3 2023 was 8981.45% at Denali Therapeutics, down from 57.96% in the prior quarter.
  • The five-year high for Operating Margin was 57.96% in Q2 2023, with the low at 7122000.0% in Q1 2021.
  • Average Operating Margin over 5 years is 432855.88%, with a median of 1236.26% recorded in 2019.
  • The sharpest move saw Operating Margin crashed -712031174bps in 2021, then soared 712184220bps in 2022.
  • Over 5 years, Operating Margin stood at 1236.26% in 2019, then skyrocketed by 48bps to 640.01% in 2020, then plummeted by -153bps to 1619.55% in 2021, then skyrocketed by 35bps to 1053.44% in 2022, then crashed by -753bps to 8981.45% in 2023.
  • According to Business Quant data, Operating Margin over the past three periods came in at 8981.45%, 57.96%, and 343.8% for Q3 2023, Q2 2023, and Q1 2023 respectively.